Tetra Discovery Partners Announces Additional Financing and Formation of Scientific Advisory Board

Tetra Discovery Partners (“Tetra”), a drug discovery company developing a portfolio of innovative drugs for psychiatric, neurological and inflammatory diseases, today announced additional private financing. The company has received additional financing from previous seed investor Grand Angels, as well as an investment by Johnson & Johnson Development Corporation (JJDC).

Tetra additionally announced the formation of its Scientific Advisory Board, comprised of four prominent experts in the field of neuroscience and psychiatric drug development:

Catherine D. Strader, Ph.D., Founding Partner, Synergy Partners, R&D Solutions, LLC and former Executive Vice President and Chief Scientific Officer, Schering-Plough and Vice President and Site Head, Merck Research Laboratories

Scott A. Reines, M.D., Ph.D., former Senior Vice President, Central Nervous System, Pain and Translational Medicine, Janssen Research & Development, LLC

James S. MacDonald, Ph.D., Founding Partner, Synergy Partners, R&D Solutions, LLC and former Executive Vice President, Preclinical Development, Schering Plough Research Institute

Jeffrey S. Nye, M.D., Ph.D., Vice President Neuroscience Innovation and Scientific Partnership Strategy, Janssen Research and Development, LLC, Johnson & Johnson Innovation, former Chief Medical Officer of Research and Early Development at Janssen

“These new funds will support additional work aimed at the filing of our first Investigational New Drug (IND) application for our cognition drug candidate in 2015,” said Mark Gurney, Ph.D., Chairman and Chief Executive Officer of Tetra. “Thanks to the strong, continued backing of Grand Angels, our grant support through the NIH Blueprint Neurotherapeutics Network (BPN), the National Institute of Aging, and the National Institute of Mental Health, and now the early strategic investment by JJDC and other investors, we expect to initiate human clinical trials for our first product in either Alzheimer’s disease or schizophrenia next year.

“Tetra Discovery Partners reflects the sort of innovative, high quality research being conducted in Michigan that our firm was created to support,” said Jody Vanderwel, President, Grand Angels. “Our belief in the strong potential of Tetra’s science, and the outstanding progress that the company has made in its lead program focused on the treatment of cognitive deficits and serious neurological and psychiatric diseases is now further supported by this new co- investment from JJDC.”

“Tetra welcomes the investment from JJDC and Johnson & Johnson Innovation, which reflects their stated aim of accelerating early stage innovation,” commented Dr. Gurney.

Commenting on the Tetra Scientific Advisory Board appointments overall, Dr. Gurney said, “Each of these individuals is an industry leader whose many years of expertise in the field of neuroscience drug development will be invaluable to our company as Tetra advances its subtype-selective PDE4 allosteric modulators for neurological, psychiatric, and inflammatory diseases into clinical development and eventual commercialization.”

Download PDF

Podcast

The Bio Report
January 2, 2020
Stabilizing Neuronal Connections to Treat Cognitive Impairment in Alzheimer’s

BioTech Nation Radio
April 3, 2019
Treatments for Fragile X, Alzheimer’s disease, and traumatic brain injury.

Awards

Michigan Celebrates
May 3, 2018
Michigan 50 Company to Watch 2018

GRBJ
December 12, 2016
2016 Newsmaker of the Year finalists

PM360
December 21, 2016
Innovators 2016: Startups

In The News

July 12, 2022

Tetra Therapeutics Initiates Phase 2b/3 Clinical Studies of Investigational Drug BPN14770 in Fragile X Syndrome

July 23, 2021

Tetra Therapeutics CEO Mark Gurney retires

July 23, 2021

Tetra Therapeutics Announces Retirement of Mark Gurney and Names Chad Coberly Chief Executive Officer in Planned Succession

July 11, 2021

Decades-long quest to beat Fragile X fueled by persistence, science and relentless optimism

April 30, 2021

Experimental Treatment Boosts Cognitive Function in Fragile X Syndrome

NPR

April 29, 2021

Memory Loss Drug Appears To Help People With The Genetic Disease Fragile X

April 29, 2021

Treatment Found to Improve Cognitive Function in Patients With Fragile X Syndrome

April 29, 2021

Drug boosts cognition in men with fragile X syndrome

April 29, 2021

Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial

April 29, 2021

Fragile X Treatment Shows Promise in Phase II Trial

April 22, 2021

Researchers take a big step in treating a genetic disorder closely linked to autism.

February 9, 2021

People with dementia had significantly greater risk of contracting the coronavirus.

February 9, 2021

Research documents more cases, hospitalizations and deaths.

December 11, 2020

New drug moves closer to becoming first treatment for Fragile X Syndrome

More News

Zatolmilast, an Investigational Treatment for Fragile X Syndrome, Receives Rare Pediatric Disease Designation from the U.S. FDA

OSAKA, Japan, September 27, 2023 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the U.S. Food and Drug Administration (FDA) has granted Tetra Therapeutics Inc. (hereafter “Tetra”), a Shionogi Group Company, Rare Pediatric Disease Designation for zatolmilast (BPN14770), an investigational

Read More »

Tetra Therapeutics Announces Positive Topline Results from Phase 2 Study of BPN14770 in Patients with Fragile X Syndrome

GRAND RAPIDS, Mich.–(BUSINESS WIRE)–Tetra Therapeutics, a wholly owned subsidiary of Shionogi & Co. Ltd., today announced positive topline results from its Phase 2 exploratory study in adult patients with Fragile X Syndrome (FXS). The study evaluated its lead candidate, BPN14770, a first-in-class phosphodiesterase‐4D (PDE4D) allosteric inhibitor. In this single-center, randomized,

Read More »